SCHEMBL4872325

SCHEMBL4872325

Nc1nc(O)c2nccc-2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 8/20 0.41
CDK5R1 Q15078 8/20 0.41
MMP12 P39900 6/20 0.39
PIM1 P11309 3/20 0.39
MMP2 P08253 1/20 0.39
DYRK1A Q13627 2/20 0.38
ULK1 O75385 1/20 0.38
CDK7 P50613 1/20 0.38
PRKCE Q02156 1/20 0.38
CAMK2G Q13555 1/20 0.38
RPS6KA1 Q15418 1/20 0.38
AAK1 Q2M2I8 1/20 0.38
MAP3K19 Q56UN5 1/20 0.38
CAMKK1 Q8N5S9 1/20 0.38
CAMKK2 Q96RR4 1/20 0.38
NUDT1 P36639 1/20 0.35
PLAU P00749 1/20 0.34
KDM4E B2RXH2 2/20 0.33
MAPT P10636 2/20 0.33
KMT2A Q03164 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3259988 0.80 KDM4E (0.35) KDM4EMAPTKMT2ANPC1GLA
SCHEMBL1800839 0.80 CDK5 (0.42) CDK5CDK5R1MMP12PIM1MMP2
SCHEMBL28388664 0.77 KDM4E (0.33) KDM4EMAPTKMT2ANPC1GLA
SCHEMBL4838743 0.77 MAPT (0.37) MMP12KDM4EMAPTKMT2ANPC1
SCHEMBL28888432 0.77 MMP12 (0.45) CDK5CDK5R1MMP12PIM1MMP2
SCHEMBL28389210 0.73 XDH (0.33) KDM4EMAPTKMT2AALDH1A1NPC1
SCHEMBL30610462 0.72 NPC1 (0.46) CDK5CDK5R1KDM4EMAPTKMT2A
SCHEMBL30610461 0.72 NPC1 (0.46) CDK5CDK5R1KDM4EMAPTKMT2A
SCHEMBL7878556 0.71 NUDT1 (0.37) CDK5CDK5R1PIM1DYRK1AULK1
Phenol SCHEMBL29093679 0.68 MAPK14 (0.46) KDM4EMAPTKMT2ANPC1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110950806-A Preparation method of pyrimidine cyclic hydroxy chloride by catalysis of tetraethylammonium chloride 安庆博曼生物技术有限公司 2020-04-03 CN claimed
CN-110950806-A Preparation method of pyrimidine cyclic hydroxy chloride by catalysis of tetraethylammonium chloride 安庆博曼生物技术有限公司 2020-04-03 CN disclosed
US-7390890-B2 Inhibitors of nucleoside metabolism ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2008-06-24 US disclosed
CN-100393722-C Inhibitors of nucleoside metabolism EINSTEIN COLL MED (US) 2008-06-11 CN disclosed
US-20070197561-A1 Inhibitors of nucleoside metabolism BIOCRYST PHARMACEUTICALS, INC. 2007-08-23 US disclosed
WO-2007069924-A1 DEAZAPURINE ANALOGS OF 4'-AZA-L-NUCLEOSIDES INDUSTRIAL RESEARCH LIMITED (NZ) 2007-06-21 WO disclosed
US-7211653-B2 Inhibitors of nucleoside metabolism ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2007-05-01 US disclosed
CN-1757646-A Inhibitors of nucleoside metabolism EINSTEIN COLL MED (US) 2006-04-12 CN disclosed
CN-1220695-C Inhibitors of nucleoside metabolism ALBERT EINSTEIN MEDICAL COLLAG (US) 2005-09-28 CN disclosed
EP-1023308-B1 INHIBITORS OF NUCLEOSIDE METABOLISM EINSTEIN COLL MED (US) 2005-09-07 EP disclosed
US-20050026936-A1 Inhibitors of nucleoside metabolism BIOCRYST PHARMACEUTICALS, INC. 2005-02-03 US disclosed
US-6803455-B2 PYRROLO(3,2-D)PYRIMIDIN-7-YL)-1,4-IMINO-D-RIBITOL DERIVATIVES; FOR SUPPRESSION OF T-CELL FUNCTION ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY 2004-10-12 US disclosed
US-20030096830-A1 Inhibitors of nucleoside metabolism BIOCRYST PHARMACEUTICALS, INC. 2003-05-22 US disclosed
US-6492347-B2 TREATMENT AND/OR PROPHYLAXIS OF INFECTION CAUSED BY PROTOZOAN PARASITE BY ADMINISTERING COMPOUND TO INHIBIT PURINE NUCLEOSIDE HYDROLASE, PURINE NUCLEOSIDE PHOSPHORYLASE, AND/OR PURINE PHOSPHORIBOSYL TRANSFERASE ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY 2002-12-10 US disclosed
US-20020061898-A1 Inhibitors of nucleoside metabolism BIOCRYST PHARMACEUTICALS, INC. 2002-05-23 US disclosed
US-6228847-B1 ADMINISTERING PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES AS PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR ALBERT EINSTEIN COLLEGE OF MEDICINE 2001-05-08 US disclosed
CN-1279686-A Inhibitors of nucleoside metabolism ALBERT EINSTEIN COLLAGE OF MED (US) 2001-01-10 CN disclosed
US-6066722-A Inhibitors of nucleoside metabolism ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2000-05-23 US disclosed
US-5985848-A EFFECTIVE INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE AND/OR NUCLEOSIDE HYDROLASES; TREATMENT AND/OR PROPHYLAXIS OF A PROTOZOAN INFECTION ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 1999-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026936-A1 Inhibitors of nucleoside metabolism CFH, CBR3, SLCO2B1 CDK5 2560/4885CDK5R1 2031/4885MMP12 4855/4885
US-20020061898-A1 Inhibitors of nucleoside metabolism PNP, APRT, NUDT14 CDK5 653/4885CDK5R1 1030/4885MMP12 2934/4885
US-20070197561-A1 Inhibitors of nucleoside metabolism CFH, CBR3, SLCO2B1 CDK5 2560/4885CDK5R1 2031/4885MMP12 4855/4885
US-20030096830-A1 Inhibitors of nucleoside metabolism CFH, NADK, UGT1A3 CDK5 3077/4885CDK5R1 2600/4885MMP12 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.